NCT06737913 (HAIBrave-001) is a Phase 2 clinical trial of HAI Adebrelimab in Advanced Hepatocellular Carcinoma (HCC), sponsored by Sun Yat-sen University.

Who is sponsoring NCT06737913?

NCT06737913 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT06737913?

Interventions in NCT06737913: HAI Adebrelimab, intravenous infusion (IV) of Adebrelimab (ADE), intravenous infusion (IV) of Bevacizumab (Bev.), HAIC with FOLFOX regimen, Adebrelimab and bevacizumab maintainance treatment.

What condition does NCT06737913 study?

NCT06737913 studies Advanced Hepatocellular Carcinoma (HCC).

Is NCT06737913 still recruiting?

NCT06737913 is currently recruiting now. Last updated 30 March 2026.

Last reviewed 2026-03-30 · How we verify

NCT06737913: HAIBrave-001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Recruiting now Phase 2 Last updated 30 March 2026

What this trial tests

Phase 2 trial testing HAI Adebrelimab in Advanced Hepatocellular Carcinoma (HCC) in 76 participants. Currently enrolling.

Timeline

3 January 2025

Primary endpoint
30 June 2028

31 December 2028

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	76
Start date	3 January 2025
Primary completion	30 June 2028
Estimated completion	31 December 2028
Sites	1 location across China

Drugs / interventions tested

HAI Adebrelimab
intravenous infusion (IV) of Adebrelimab (ADE) — full drug profile →
intravenous infusion (IV) of Bevacizumab (Bev.) — full drug profile →
HAIC with FOLFOX regimen
Adebrelimab and bevacizumab maintainance treatment — full drug profile →

Conditions studied

Advanced Hepatocellular Carcinoma (HCC) — all drugs for Advanced Hepatocellular Carcinoma (HCC) →

Sponsor

Sun Yat-sen University

Who can join

18 and older, any sex, with Advanced Hepatocellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of Adabrelimab (arterial or intravenous administration) combined with hepatic artery FOLFOX infusion chemotherapy and Bevacizumab as the first-line treatment of advanced stage hepatocellular carcinoma. Patients will be randomized 1:1 etither to receive hepatic arterial infusion(HAI) Adabrelimab group or IV Adabrelimab group, and both groups will receive HAI FOLFOX chemotherapy and IV Bevacizumab.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Hepatocellular Carcinoma (HCC)

Currently open trials in the same condition.

NCT07493044 — An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma · Phase 1 · recruiting
NCT07500220 — Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC · Phase 1, PHASE2 · recruiting
NCT07123545 — Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT06902389 — A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07039201 — A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC) · NA · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06737913 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 30 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06737913.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing